Summarv We have characterised an etoposide-resistant subline of the small-cell lung cancer cell line.
In most patients with small-cell lung cancer (SCLC) tumours will respond initially to combination chemotherapy followed bv a recurrence of cancer which is refractory to multiple cytotoxic agents (Harper et al.. 1982) . Multidrug-resistant SCLC tumours. like other bronchial carcinomas. have generally not been found to have overexpression of P- glycoprotein. a transmembrane protein which in other human tumours has been demonstrated to produce resistance by acting as an energy-dependent drug export transporter . The pattern of anti-cancer drug resistance seen in SCLC cells in vitro is often different from that of P-glycoprotein-mediated multidrug resistance (Giaccone et al.. 1992 : Jensen et al.. 1993 . Fur- thermore. multidrug resistance in cultured lung cancer cells is poorly reversed by chemosensitisers that are effective in cells which overexpress P-glycoprotein (Cole et al.. 1989) . There has been considerable recent interest in discovering the mechanisms underlying non-P-glycoprotein-mediated multidrug resistance in human lung cancer cells (Bergh et al.. 1990: Doyle. 1993 ).
The gene for a novel drug transporter. termed the multidrug resistance-associated protein (MRP), was recently found to be amplified and overexpressed in a doxorubicin-selected SCLC cell line which is multiply drug resistant but does not overexpress P-glvcoprotein (Cole et al.. 1992) . Several other doxorubicin-selected cancer cell lines have subsequently been found to have overexpression of the MRP gene (Slovak et al.. 1993 : Barrand et al.. 1994 . A full-length cDNA of MRP has been cloned, and two independent transfection experiments have demonstrated that cells transfected with MRP expression vectors demonstrate resistance to doxorubicin. etoposide and vincristine proportional to the levels of the 190 kDa membrane protein expressed by the MRP gene (Grant et al.. 1994a; Kruh et al.. 1994) . Overexpression of MRP has recently been found to result in increased ATPdependent glutathione S-conjugate transport (Jedlitschky et al., 1994 : Muller et al.. 1994 that MRP may contribute to clinical drug resistance in human cancer (Schneider et al.. 1995) .
Etoposide is one of the most clinically important drugs in the frontline treatment of SCLC tumours (Cavalli et al.. 1978) . The activity of etoposide results from a specific interaction of the drug with the nuclear enzyme topoisomerase II (Yang et al.. 1985) . This enzyme has the ability to alter the topological state of DNA and has a critical role in DNA replication. chromosomal segregation and RNA transcription (Liu. 1989 : Osheroff et al.. 1991 Chemosensitzivit!u testing MTT (3-(4.5-dimethy lthiazol-2-yl)X-1.5-dipeny ltetrazolium bromide) assays A-ere performed with minor modifications of the method of Mosmann (1983 temperature with 'MI-labelled goat anti-rabbit IgG (Amersham) in TSM buffer. The membranes were washed five times as before then developed for 6-24 h.
Western blotting for MRP was performed using detergentsolubilised membrane proteins as previously described (Chen et al., 1990 (Krishnamachary and Center, 1993 Northern blot analysis A 1 kb fragment from the 3' region of MRP cDNA cloned into an EcoRI site in pGEM-3Zf(+), was obtained from Dr S Cole. RNA was prepared from cells using the RNA-STAT-60 kit. The cDNA clone, which was termed pmrp 10.1, was used for labelling by random priming with [_-32P]dCTP (Prime-a-Gene labelling system, Promega) and probing of Northern blots. Twenty micrograms of total RNA was separated on a 1.2% agarose gel in formaldehyde 4-morpholinepropanesulphonic acid buffer. After transfer onto Immobilon-N polyvinylidene difluoride membranes (Millipore, Bedford, MA. USA), the membrane was prehybridised overnight and hybridised at 42°C for 20 h with the labelled MRP probe in 50% formamide. After washing, the membrane was exposed to X-ray film for 4-16 h at -70°C with intensifying screens. To estimate variation in RNA loading of the gel, the blots were stripped and rehybridised with a 3-P-labelled cDNA probe from the 3' region of mouse fractin (Tokunaga et al., 1986) . Relative levels of MRP and fractin mRNAs were determined by densitometry. (Table II) . The UMCC-1 VP cell line was also found to have no cross-resistance to taxol or thiotepa, and only 2-fold resistance to idarubicin, melphalan and cisplatin, relative to the UMCC-1 line (Table I) .
Drug accumulation and efflux
The UMCC-1,,VP subline had markedly reduced accumulation of etoposide compared with the sensitive parental line Figure 5 ) (Krishnamachary and Center, 1993 were readily detectable in a PCR reaction using RNA from these lines (Figure 5 ). The 575 bp PCR product was subsequently cut out of the gel and purified by phenol-chloroform extraction and ethanol precipitation. The DNA was sequenced on an Applied Biosystems automated sequencer. using the original PCR primer sequences as templates. DNA sequence analysis revealed that the PCR product sequence was consistent with authentic MRP (data not shown).
Relative (Barrand et al.. 1993 . 1994 : Zaman et al.. 1993 . MRP overexpression has also been demonstrated in anthracycine-selected leukaemia and fibrosarcoma sublines (Krishnamachary and Center. 1993: Slovak et al., 1993) .
Antisera derived against synthetic MRP proteins demonstrate that the MRP protein is 195 kDa on immunoblots and enriched in membrane fractions (Krishnamachary and Center. 1993) . Treatment of HL60/ADR cells wtih tunicamycin results in the appearance of a 165 kDa band reactive with the antipeptide serum (Krishnamachary and Center, 1993 
